Eisai Expands into Canada
News May 11, 2010
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. has announces the establishment of Eisai Limited in Canada, the world’s ninth largest pharmaceutical market.
As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region”
“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region,” said Hajime Shimizu, Chairman and CEO, Eisai Inc. “Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Chemists Develop Method to Synthesize Drugs From Renewable PrecursorsNews
Researchers have developed a new approach to the synthesis of benzofurans from cheap raw materials.READ MORE